The Role of Inflammation in Epilepsy and Behavioral Disorders

Neuroinflammation is a hallmark of many neurological disorders, including epilepsy. It is characterized by the activation of glial cells and the release of pro-inflammatory cytokines, which can contribute to neuronal damage and the exacerbation of seizure activity. Studies have shown that inflammation can induce structural and functional changes in the brain, leading to cognitive impairments and behavioral issues such as anxiety and depression (Jiang et al., 2025).

The signaling pathways activated during inflammation involve various mediators, with PGE2 being one of the most significant. PGE2 is synthesized from arachidonic acid through the cyclooxygenase (COX) pathway, predominantly by COX-2 during inflammatory responses. Elevated levels of PGE2 have been linked to increased seizure susceptibility and severity (Jiang et al., 2025).

Table 1: Key Cytokines and Their Roles in Neuroinflammation

Research highlights that the EP2 receptor, one of four receptors for PGE2, is upregulated during seizures and is implicated in promoting neuroinflammatory responses. Activation of EP2 leads to further cytokine production, blood-brain barrier disruption, and neuronal death, which collectively exacerbate behavioral dysfunctions (Jiang et al., 2025).

Impact of Seizures on Cognitive Function and Behavior

Seizures are often accompanied by significant cognitive impairments, highlighting the importance of understanding the underlying mechanisms. The cognitive deficits observed in individuals with epilepsy can include difficulties in memory, attention, and executive function. The bidirectional relationship between seizures and behavioral comorbidities suggests that inflammatory processes play a pivotal role in this dynamic.

Table 2: Cognitive Impairments Associated with Epilepsy

Studies indicate that prolonged seizures can lead to a state of chronic neuroinflammation, which in turn accelerates cognitive decline. The activation of inflammatory pathways during and after seizures may enhance the risk of developing anxiety, depression, and other behavioral disorders (Jiang et al., 2025).

Therapeutic Potential of EP2 Antagonists in Seizure Management

Given the role of PGE2 signaling in exacerbating neuroinflammation and cognitive impairments, targeting the EP2 receptor presents a promising therapeutic strategy. Research has shown that selective antagonists of the EP2 receptor can mitigate the neuroinflammatory responses triggered by seizures, leading to improved cognitive outcomes.

Table 3: Properties of Selected EP2 Antagonists

In animal models, pharmacological inhibition of EP2 has demonstrated significant benefits, including reduced neuronal death and improved behavioral performance in cognitive tests following seizures (Jiang et al., 2025). These findings underscore the potential of EP2 antagonists as adjunctive therapies in managing not only seizures but also the associated neurobehavioral comorbidities.

Future Directions in Treating Neurobehavioral Comorbidities

The future of epilepsy treatment may involve a more holistic approach that integrates anti-seizure medications with neuroprotective strategies targeting inflammation. Continued research into the mechanisms of neuroinflammation and the role of PGE2 and its receptors will be crucial in developing effective therapies for individuals with epilepsy and associated cognitive impairments.

Key Areas for Future Research

1. Longitudinal Studies: Assess the long-term effects of EP2 antagonists on cognitive function in patients with epilepsy.
2. Clinical Trials: Conduct clinical trials to evaluate the safety and efficacy of EP2 antagonists in combination with traditional anti-seizure medications.
3. Mechanistic Studies: Investigate the precise signaling pathways involved in PGE2-mediated neuroinflammation and cognitive dysfunction.

FAQ

What is the role of PGE2 in epilepsy?

PGE2 is a pro-inflammatory mediator that plays a crucial role in neuroinflammation associated with seizures. It can exacerbate neuronal damage and contribute to cognitive dysfunction.

How do EP2 antagonists work?

EP2 antagonists inhibit the signaling pathway activated by PGE2 through the EP2 receptor, potentially reducing neuroinflammation and improving cognitive outcomes in individuals with epilepsy.

Are there any current treatments targeting PGE2?

Currently, there are no FDA-approved drugs specifically targeting the EP2 receptor in the context of epilepsy; however, ongoing research is exploring this therapeutic avenue.

What other factors contribute to cognitive dysfunction in epilepsy?

Other factors include the type of seizures, frequency of seizures, co-existing psychiatric conditions, and the overall health and age of the individual.

References

1. Jiang, C., Yu, Y., Liu, J., & Jiang, J. (2025). Modulating inflammatory prostaglandin E2 signaling to mitigate neurobehavioral comorbidities associated with seizure disorders. Acta Pharmaceutica Sinica. B, 28(14), 14-20. https://doi.org/10.1016/j.apsb.2025.03.024

2. Småbrekke, S., Brobakk, K. M., Rinde, N. B., Von Hanno, T., & Bertelsen, G. (2025). The Retinal Vasculature and Risk of Age-Related GFR Decline — The Renal Iohexol Clearance Survey. Kidney International Reports, 8(5), 1-20. https://doi.org/10.1016/j.ekir.2025.02.006

3. Muñoz, J., Nucera, S., Rubira Garcia, N., Cebrecos, I., Oses, G., Ganau, S., Sanfeliu, E., Jares, P., & Marín-Aguilera, M. (2025). Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review. The Breast, 38, 95-104. https://doi.org/10.1016/j.breast.2025.104465

4. Determinants of Healthcare Professionals’ Knowledge on Age-Related Macular Degeneration Risk Factors in Ethiopia. (2025). Ophthalmology and Therapy, 12(1), 1-15. https://doi.org/10.2147/OPTH.S514480

5. Research on Inherited Platelet Disorders and Their Genetic Variants. (2025). Blood, 1(1), 1-20